A medical cannabis trial will target 20000 UK patients

A project supported by the Royal College of Psychiatrists aims to establish the largest database on medical cannabis use in Europe.

Up to 20000 patients in the UK will receive medical cannabis over a two year period as part of a initiative which aims to create the largest body of data in Europe.

Although medical marijuana was legalized in the UK a year ago, it remains inaccessible to many patients. . "Medical cannabis is still out of reach for far too many people," said Professor David Nutt of Drug Science, the organization behind the launch of the Twenty21 project, which will supply 20 000 patients with cannabis. 'here the end 2021.

"Patients are heavily in debt because of the cost of prescriptions from the private sector or are criminalized when they are forced to turn to the black market. They deserve none of this, and the prescription situation must change. "

The project - to be launched and supported by the Royal College of Psychiatrists (RCP) - aims to create the largest body of medical cannabis data in Europe to convince decision makers that the plant should be made widely available. and affordable than other drugs.

Since the legalization, doctors are reluctant to prescribe cannabis because of the supposed lack of evidence of its effectiveness. They are also concerned that it will be overvalued by a nascent, profit-maximizing industry.

The Twenty21 project will investigate the effects of cannabis on patients with chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, Tourette's syndrome, anxiety disorder or a history of substance abuse. .

"The PCR hopes that this project will address the lack of evidence on the use of cannabis-based medicinal products in all health settings, including mental health," said Professor Wendy Burn, PCR Chair. .

CBD Oil - 2,75% - 10ml
Tags : Chronic PainSearchstatisticalTreatmentUK